Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

5-Fluorouracil (5-FU) and oral fluoropyrimidines, such as capecitabine, are widely used in the treatment of cancer, especially gastrointestinal tumors and breast cancer, but their administration can produce serious and even lethal toxicity. This toxicity is often related to the partial or complete d...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2022-03, Vol.24 (3), p.483-494
Main Authors: García-Alfonso, P., Saiz-Rodríguez, M., Mondéjar, R., Salazar, J., Páez, D., Borobia, A. M., Safont, M. J., García-García, I., Colomer, R., García-González, X., Herrero, M. J., López-Fernández, L. A., Abad-Santos, F.
Format: Article
Language:English
Subjects:
Capecitabine - therapeutic use
Dihydrouracil Dehydrogenase (NADP) - genetics
Fluorouracil - therapeutic use
Genotyping Techniques - standards
Humans
Medicine
Medicine & Public Health
Neoplasms - drug therapy
Neoplasms - genetics
Oncology
Patient Selection
Polymorphism, Single Nucleotide
Special
Special Article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:5-Fluorouracil (5-FU) and oral fluoropyrimidines, such as capecitabine, are widely used in the treatment of cancer, especially gastrointestinal tumors and breast cancer, but their administration can produce serious and even lethal toxicity. This toxicity is often related to the partial or complete deficiency of the dihydropyrimidine dehydrogenase (DPD) enzyme, which causes a reduction in clearance and a longer half-life of 5-FU. It is advisable to determine if a DPD deficiency exists before administering these drugs by genotyping DPYD gene polymorphisms. The objective of this consensus of experts, in which representatives from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology participated, is to establish clear recommendations for the implementation of genotype and/or phenotype testing for DPD deficiency in patients who are candidates to receive fluoropyrimidines. The genotyping of DPYD previous to treatment classifies individuals as normal, intermediate, or poor metabolizers. Normal metabolizers do not require changes in the initial dose, intermediate metabolizers should start treatment with fluoropyrimidines at doses reduced to 50%, and poor metabolizers are contraindicated for fluoropyrimidines.
ISSN:1699-048X
1699-3055
DOI:10.1007/s12094-021-02708-4